Cited by 481HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentCervical Cancer and HPV Research

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women.

Open access

Nel, Annalene, van Niekerk, Neliëtte, Kapiga, Saidi, Bekker, Linda-Gail, Gama, Cynthia, Gill, Katherine, Kamali, Anatoli, Kotze, Philip, Louw, Cheryl, Mabude, Zonke, Miti, Nokuthula, Kusemererwa, Sylvia, Tempelman, Hugo, Carstens, Hannelie, Devlin, Brid, Isaacs, Michelle, Malherbe, Mariëtte, Mans, Winel, Nuttall, Jeremy, Russell, Marisa, Ntshele, Smangaliso, Smit, Marlie, Solai, Leonard, Spence, Patrick, Steytler, John, Windle, Kathleen, Borremans, Maarten, Resseler, Sophie, Van Roey, Jens, Parys, Wim, Vangeneugden, Tony, Van Baelen, Ben, Rosenberg, Zeda·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1602046

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The incidence of human immunodeficiency virus (HIV) infection remains high among women in sub-Saharan Africa. We evaluated the safety and efficacy of extended use of a vaginal ring containing dapivirine for the prevention of HIV infection in 1959 healthy, sexually active women, 18 to 45 years of age, from seven communities in South Africa and Uganda. METHODS: In this randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned participants in a 2:1 ratio to receive vaginal rings containing either 25 mg of dapivirine or placebo. Participants inserted the rings themselves every 4 weeks for up to 24 months. The primary efficacy end point was the rate of HIV type 1 (HIV-1) seroconversion. RESULTS: A total of 77 participants in the dapivirine group underwent HIV-1 seroconversion during 1888 person-years of follow-up (4.1 seroconversions per 100 person-years), as compared with 56 in the placebo group who underwent HIV-1 seroconversion during 917 person-years of follow-up (6.1 seroconversions per 100 person-years). The incidence of HIV-1 infection was 31% lower in the dapivirine group than in the placebo group (hazard ratio, 0.69; 95% confidence interval [CI], 0.49 to 0.99; P=0.04). There was no significant difference in efficacy of the dapivirine ring among women older than 21 years of age (hazard ratio for infection, 0.63; 95% CI, 0.41 to 0.97) and those 21 years of age or younger (hazard ratio, 0.85; 95% CI, 0.45 to 1.60; P=0.43 for treatment-by-age interaction). Among participants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations were detected in 14 of 77 participants in the dapivirine group (18.2%) and in 9 of 56 (16.1%) in the placebo group. Serious adverse events occurred more often in the dapivirine group (in 38 participants [2.9%]) than in the placebo group (in 6 [0.9%]). However, no clear pattern was identified. CONCLUSIONS: Among women in sub-Saharan Africa, the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo. (Funded by the International Partnership for Microbicides; ClinicalTrials.gov number, NCT01539226 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1602046

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citation
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.
Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020298 · Cited by 2,451
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Self-citation
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506110 · Cited by 772
Self-citation
Women’s Experiences with Oral and Vaginal Pre-Exposure Prophylaxis: The VOICE-C Qualitative Study in Johannesburg, South Africa
van der Straten, A., Stadler, J., Montgomery, E., Hartmann, M., Magazi, B., Mathebula, F., Schwartz, K. D., Laborde, N. D., & Soto-Torres, L. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089118 · Cited by 259
Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
Amico, K. R., & Stirratt, M. J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu266 · Cited by 117
Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa
Nel, A. M., Bekker, L., Bukusi, E. A., Hellström, E., Kotze, P. L., Louw, C. E., Martinson, F. E. A., Masenga, G. G., Montgomery, E., Ndaba, N. D., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147743 · Cited by 113
Self-citation

Flagged first, then by citations

Show all 16 references

Research works printed but not linked: 1

Wensing AM, 2015, Top Antivir Med, 23, 132

Sorted by citations

Items 101–200 of 481

Advancing the use of Long‐Acting Extended Delivery formulations for HIV prevention in sub‐Saharan Africa: challenges, opportunities, and recommendations
Mgodi, N. M., Murewanhema, G., Moyo, E., Samba, C., Musuka, G., Dzinamarira, T., & Brown, J. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26115 · Cited by 36
Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
Mahomed, S., Garrett, N., Capparelli, E. V., Osman, F., Harkoo, I., Yende‐Zuma, N., Gengiah, T. N., Archary, D., Samsunder, N., Baxter, C., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac041 · Cited by 34
Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study
van der Straten, A., Ryan, J., Reddy, K., Etima, J., Taulo, F., Mutero, P., Taylor, J., Piper, J. M., Musara, P., & the MTN‐041/MAMMA Study Team (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25536 · Cited by 34
Multipurpose Prevention Technologies: Opportunities and Challenges to Ensure Advancement of the Most Promising MPTs
Holt, B. Y., Turpin, J. A., & Romano, J. (2021) · Frontiers in Reproductive Health · doi:10.3389/frph.2021.704841 · Cited by 34
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
Parikh, U. M., & Mellors, J. W. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000746 · Cited by 34
Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy
Makanani, B., Balkus, J. E., Jiao, Y., Noguchi, L., Palanee‐Phillips, T., Mbilizi, Y., Moodley, J., Kintu, K., Reddy, K., Kabwigu, S., et al. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001861 · Cited by 33
Impact of vaginal microbiome communities on HIV antiretroviral-based pre-exposure prophylaxis (PrEP) drug metabolism
Cheu, R. K., Gustin, A. T., Lee, C. Y., Schifanella, L., Miller, C. J., Ha, A., Kim, C., Rodriguez, V. J., Fischl, M. A., Burgener, A., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009024 · Cited by 32
Patient-Led Decision-Making for HIV Preexposure Prophylaxis
Irie, W. C., Solleveld, P., Seidman, D. L., Dehlendorf, C. E., Marcus, J. L., & Krakower, D. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00535-w · Cited by 33
HIV Pathogenesis in the Human Female Reproductive Tract
Rodríguez‐García, M., Connors, K. A., & Ghosh, M. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00546-1 · Cited by 36
Recent advances in electrospun nanofiber vaginal formulations for women's sexual and reproductive health
Cazorla-Luna, R., Ruíz, R., Veiga, M.-D., Malcolm, K. R., & Lamprou, D. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121040 · Cited by 32
Single Dose Topical Inserts Containing Tenofovir Alafenamide Fumarate and Elvitegravir Provide Pre- and Post-Exposure Protection Against Vaginal Shiv Infection in Macaques
Dobard, C., Peet, M. M., Nishiura, K., Holder, A. N., Dinh, C. T., Mitchell, J. M., Khalil, G., Pan, Y., Singh, O., McCormick, T. J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104361 · Cited by 33
HIV prevention is not all about HIV – using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection
Vickerman, P. T., Quaife, M., Kilbourne‐Brook, M., Mvundura, M., Eakle, R., & Terris‐Prestholt, F. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05399-4 · Cited by 31
Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses
Hu, Y., Zhang, J., Musharrafieh, R. G., Ma, C., Hau, R. K., & Wang, J. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.07.016 · Cited by 31
Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring
Balkus, J. E., Brown, E. R., Palanee‐Phillips, T., Kiweewa, F. M., Mgodi, N. M., Naidoo, L., Mbilizi, Y., Jeenarain, N., Gaffoor, Z., Siva, S. S., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001556 · Cited by 31
Clinically advancing and promising polymer-based therapeutics
Souery, W. N., & Bishop, C. J. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.11.044 · Cited by 31
Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost‐effectiveness
Glaubius, R. L., Ding, Y., Penrose, K. J., Hood, G., Engquist, E., Mellors, J. W., Parikh, U. M., & Abbas, U. L. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25282 · Cited by 30
Facilitating engagement with PrEP and other HIV prevention technologies through practice‐based combination prevention
Skovdal, M. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25294 · Cited by 30
Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV
Philbin, M. M., & Perez‐Brumer, A. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000723 · Cited by 29
From policy to practice: uptake of pre-exposure prophylaxis among adolescent girls and young women in United States President's Emergency Plan for AIDS Relief-supported countries, 2017–2020
Patel, P., Sato, K. N., Bhandari, N., Kanagasabai, U., Schelar, E., Cooney, C., Eakle, R., Klucking, S., Toiv, N., & Saul, J. R. (2022) · AIDS · doi:10.1097/qad.0000000000003103 · Cited by 29
FAME ‐04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir
Bunge, K. E., Dezzutti, C. S., Hendrix, C. W., Marzinke, M. A., Spiegel, H. M. L., Moncla, B. J., Schwartz, J. L., Meyn, L. A., Richardson‐Harman, N., Rohan, L. C., et al. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25156 · Cited by 29
Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings
Hoesley, C. J., Chen, B. A., Anderson, P. L., Dezzutti, C. S., Strizki, J., Sprinkle, C., Heard, F., Bauermeister, J. A., Hall, W., Jacobson, C. E., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy653 · Cited by 28
Reaching at-risk women for PrEP delivery: What can we learn from clinical trials in sub-Saharan Africa?
Stankevitz, K., Schwartz, K. D., Hoke, T., Li, Y., Lanham, M., Mahaka, I. C., & Mullick, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218556 · Cited by 28
The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study
Smith, J., Garnett, G. P., & Hallett, T. B. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa296 · Cited by 28
Development of pH-sensitive vaginal films based on methacrylate copolymers for topical HIV-1 pre-exposure prophylaxis
Notario-Pérez, F., Galante, J., Martín-Illana, A., Cazorla-Luna, R., Sarmento, B. F. C. C., Ruíz, R., das Neves, J., & Veiga, M.-D. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.019 · Cited by 28
The effect of different contraceptive methods on the vaginal microbiome
Bastianelli, C., Farris, M., Bianchi, P., & Benagiano, G. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917373 · Cited by 28
How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub‐Saharan Africa: a mixed methods analysis
Roberts, S. T., Mancuso, N., Williams, K., Nabunya, H. K., Mposula, H., Mugocha, C., Mvinjelwa, P., Garcia, M., Szydlo, D. W., Soto-Torres, L. E., et al. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26189 · Cited by 28
Impact of ring size and drug loading on the pharmacokinetics of a combination dapivirine-darunavir vaginal ring in cynomolgus macaques
Murphy, D. J., Desjardins, D., Boyd, P., Dereuddre‐Bosquet, N., Stimmer, L., Caldwell, A., Grand, R. L., Kelly, C. G., Roey, J. V., & Malcolm, K. R. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.08.051 · Cited by 28
Non- Lactobacillus -Dominant and Polymicrobial Vaginal Microbiomes Are More Common in Younger South African Women and Predictive of Increased Risk of Human Immunodeficiency Virus Acquisition
Wang, Y., Noël‐Romas, L., Perner, M., Knodel, S., Molatlhegi, R. P., Hoger, S., Birse, K., Zuend, C. F., McKinnon, L. R., & Burgener, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac938 · Cited by 29
Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women
Chen, B. A., Zhang, J., Gundacker, H. M., Hendrix, C. W., Hoesley, C. J., Salata, R. A., Dezzutti, C. S., van der Straten, A., Hall, W., Jacobson, C. E., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy654 · Cited by 27
Self-citation
Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring
Noguchi, L., Hoesley, C. J., Kelly, C., Scheckter, R., Bunge, K. E., Nel, A. M., Marzinke, M. A., Hendrix, C. W., Dezzutti, C. S., Hillier, S. L., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01930-18 · Cited by 27
Self-citation
Generating CHARISMA: Development of an Intervention to Help Women Build Agency and Safety in Their Relationships While Using PrEP for HIV Prevention
Hartmann, M., Lanham, M., Palanee‐Phillips, T., Mathebula, F., Tolley, E. E., Peacock, D., Pascoe, L. A., Zissette, S., Roberts, S. T., Wagner, L. D., et al. (2019) · AIDS Education and Prevention · doi:10.1521/aeap.2019.31.5.433 · Cited by 27
HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals
Poteat, T., & Radix, A. E. (2020) · Drugs · doi:10.1007/s40265-020-01313-z · Cited by 27
Pregnant and breastfeeding women’s prospective acceptability of two biomedical HIV prevention approaches in Sub Saharan Africa: A multisite qualitative analysis using the Theoretical Framework of Acceptability
Sekhon, M., van der Straten, A., & on behalf of the MTN-041/MAMMA Study Team (2021) · PLoS ONE · doi:10.1371/journal.pone.0259779 · Cited by 27
Nanotechnologies for early diagnosis, in situ disease monitoring, and prevention
Wu, T., Chiu, H., Yu, J., Cautela, M. P., Sarmento, B. F. C. C., das Neves, J., Catala, C., Pérez, N. P., Guerrini, L., Álvarez‐Puebla, R. A., et al. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48063-5.00001-0 · Cited by 25
Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women
Bunge, K. E., Levy, L., Szydlo, D. W., Zhang, J., Gaur, A. H., Reirden, D. H., Mayer, K. H., Futterman, D. C., Hoesley, C. J., Hillier, S. L., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002244 · Cited by 25
Self-citation
Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting
Romano, J., Baum, M. M., Demkovich, Z. R., Diana, F., Dobard, C., Feldman, P. L., Garcia-Lerma, J. G., Grattoni, A., Gunawardana, M., Ho, D., et al. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0028 · Cited by 25
Physiologically‐based pharmacokinetic model of vaginally administered dapivirine ring and film formulations
Kay, K., Shah, D. K., Rohan, L. C., & Bies, R. R. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13625 · Cited by 25
Novel Application of Hot Melt Extrusion for the Manufacturing of Vaginal Films Containing Microbicide Candidate Dapivirine
Regev, G., Patel, S. K., Moncla, B. J., Twist, J. N., Devlin, B., & Rohan, L. C. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1442-8 · Cited by 25
Self-citation
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States
Liu, A., Islas, C. P. D., Gundacker, H. M., Neradilek, B., Hoesley, C. J., van der Straten, A., Hendrix, C. W., Beamer, M. A., Jacobson, C. E., McClure, T., et al. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25747 · Cited by 25
Self-citation
Packing Polymorphism of Dapivirine and Its Impact on the Performance of a Dapivirine-Releasing Silicone Elastomer Vaginal Ring
McCoy, C. F., Murphy, D. J., Boyd, P., Derrick, T., Spence, P. L., Devlin, B., & Malcolm, K. R. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.026 · Cited by 25
Self-citation
Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
Bhavaraju, N., Shears, K., Schwartz, K. D., Mullick, S., Jeckonia, P., Murungu, J., Persaud, U., Vij, A., & Torjesen, K. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00577-8 · Cited by 24
On-demand microbicide products: design matters
Patel, S. K., & Rohan, L. C. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0385-4 · Cited by 24
Innovations in the biomedical prevention, diagnosis, and service delivery of HIV and other sexually transmitted infections
Peters, R. P. H., Grinsztejn, B. G. J., Celum, C., Mayer, K. H., Molina, J., Delany‐Moretlwe, S., Ngure, K., Rueda, S. T., Guy, R., Reiss, P., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00983-3 · Cited by 29
Self-citation
HIV Antiretroviral Pre‐Exposure Prophylaxis: Development Challenges and Pipeline Promise
Hendrix, C. W. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1227 · Cited by 23
Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection
Stalter, R. M., Pintye, J. C., & Mugwanya, K. K. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1931680 · Cited by 22
Future of nonnucleoside reverse transcriptase inhibitors
Sluis‐Cremer, N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720975115 · Cited by 22
Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention
Nicol, M. R., Corbino, J. A., & Cottrell, M. L. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1270 · Cited by 22
Antiviral Classification
Li, G., Jing, X., Zhang, P., & Clercq, E. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814515-9.00126-0 · Cited by 22
The Influence of Cervicovaginal Microbiota on Mucosal Immunity and Prophylaxis in the Battle against HIV
Farcasanu, M., & Kwon, D. S. (2018) · Current HIV/AIDS Reports · doi:10.1007/s11904-018-0380-5 · Cited by 21
High acceptability of a contraceptive vaginal ring among women in Kigali, Rwanda
Kestelyn, E., Nuil, J. I. V., Umulisa, M. M., Umutoni, G., Uwingabire, A., Mwambarangwe, L., Uwineza, M., Agaba, S. K., Crucitti, T., van de Wijgert, J. H. H. M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199096 · Cited by 21
First Impressions Matter: How Initial Worries Influence Adherence to the Dapivirine Vaginal Ring
van der Straten, A., Browne, E. N., Shapley‐Quinn, M. K., Brown, E. R., Reddy, K., Scheckter, R., Soto-Torres, L. E., Palanee‐Phillips, T., Baeten, J. M., Mensch, B., et al. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002028 · Cited by 21
Pharmaceutical Approaches to HIV Treatment and Prevention
Yavuz, B., Morgan, J. L., Showalter, L., Crakes, K. R., Dandekar, S., Herrera, C., LiWang, P. J., & Kaplan, D. L. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800054 · Cited by 22
Vaginal multipurpose prevention technologies: promising approaches for enhancing women’s sexual and reproductive health
Fernandes, T., Baxi, K., Sawarkar, S. P., Sarmento, B. F. C. C., & das Neves, J. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1728251 · Cited by 20
A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use
Kestelyn, E., Agaba, S. K., Nuil, J. I. V., Uwineza, M., Umulisa, M. M., Mwambarangwe, L., Ndagijimana, J. C., Baetselier, I. D., Buyze, J., Delvaux, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197572 · Cited by 20
PrEP uptake and HIV viral suppression when PrEP is integrated into Ugandan ART clinics for HIV-negative members of HIV-serodifferent couples: a stepped wedge cluster randomized trial
Heffron, R., Muwonge, T. R., Thomas, K. K., Nambi, F., Nakabugo, L., Kibuuka, J., Thomas, D., Feutz, E., Meisner, A., Ware, N. C., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101611 · Cited by 20
Men’s Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe
Montgomery, E., Katz, A. W. K., Duby, Z., Mansoor, L. E., Morar, N. S., Naidoo, K., Tsidya, M., Chitukuta, M., Guma, V., Tenza, S., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-020-03119-2 · Cited by 19
Assessing pregnancy and neonatal outcomes in Malawi, South Africa, Uganda, and Zimbabwe: Results from a systematic chart review
Balkus, J. E., Neradilek, M. B., Fairlie, L., Makanani, B., Mgodi, N. M., Mhlanga, F., Nakabiito, C., Mayo, A., Harrell, T. M., Piper, J. M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248423 · Cited by 19
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study
Thurman, A. R., Brache, V., Cochón, L., Ouattara, L. A., Chandra, N., Jacot, T. A., Yousefieh, N., Clark, M. R., Peet, M. M., Hanif, H., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275794 · Cited by 21
User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences
Guthrie, K. M., Rosen, R. K., Vargas, S. E., Getz, M. L., Dawson, L. N., Guillen, M., Ramirez, J. J., Baum, M. M., & Vincent, K. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197269 · Cited by 19
Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region
Pines, H. A., Strathdee, S. A., Hendrix, C. W., Bristow, C., Vera, A., Magis-Rodríguez, C. L., Martinez, G., Semple, S. J., & Patterson, T. (2018) · International Journal of STD & AIDS · doi:10.1177/0956462418793038 · Cited by 19
Targeted microbicides for preventing sexual HIV transmission
Coutinho, C., Sarmento, B. F. C. C., & das Neves, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.030 · Cited by 19
Comprehensive HIV risk reduction interventions for 2020 and beyond
Velloza, J., Delany‐Moretlwe, S., & Baeten, J. M. (2019) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000567 · Cited by 18
Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel
Bashi, Y. H. D., Murphy, D. J., McCoy, C. F., Boyd, P., Brown, L., Kihara, M. T., Martin, F., McMullen, N., Kleinbeck, K., Dangi, B., et al. (2021) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2021.100091 · Cited by 18
Self-citation
Planning for decentralized, simplified prEP: Learnings from potential end users in Ga-Rankuwa, gauteng, South Africa
Mataboge, P., Nzenze, S. A., Mthimkhulu, N., Mazibuko, M., Kutywayo, A., Butler, V., Naidoo, N., & Mullick, S. (2023) · Frontiers in Reproductive Health · doi:10.3389/frph.2022.1081049 · Cited by 18
Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)
Ngure, K., Friedland, B., Szydlo, D. W., Roberts, S. T., Garcia, M., Levy, L., Akello, C. A., Reddy, K., Palanee‐Phillips, T., Macdonald, P., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287525 · Cited by 18
Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01)
Weld, E. D., McGowan, I., Anton, P. A., Fuchs, E. J., Ho, K. S., Carballo‐Diéguez, A., Rohan, L. C., Giguere, R., Brand, R. M., Edick, S., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad535 · Cited by 18
Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception
Balkus, J. E., Palanee‐Phillips, T., Reddy, K., Siva, S. S., Harkoo, I., Nakabiito, C., Kintu, K., Nair, G., Chappell, C. A., Kiweewa, F. M., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001455 · Cited by 18
Generation of a Dual-Target, Safe, Inexpensive Microbicide that Protects Against HIV-1 and HSV-2 Disease
Zuend, C. F., Nomellini, J. F., Smit, J., & Horwitz, M. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-21134-1 · Cited by 18
Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Liu, A., Zhang, J., Anderson, P. L., Wagner, T. M., Pan, Z., Peda, M., Gomez, K., Beamer, M. A., Jacobson, C. E., Strizki, J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy652 · Cited by 18
Integrated provision of topical pre‐exposure prophylaxis in routine family planning services in South Africa: a non‐inferiority randomized controlled trial
Mansoor, L. E., Yende‐Zuma, N., Baxter, C., Mngadi, K. T., Dawood, H., Gengiah, T. N., Samsunder, N., Schwartz, J. L., Doncel, G. F., & Karim, Q. A. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25381 · Cited by 18
Modeling HIV Pre-Exposure Prophylaxis
Straubinger, T., Kay, K., & Bies, R. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01514 · Cited by 18
Caerin 1 Antimicrobial Peptides that Inhibit HIV and Neisseria May Spare Protective Lactobacilli
Rollins‐Smith, L. A., Smith, P. B., Ledeczi, A. M., Rowe, J. M., & Reinert, L. K. (2020) · Antibiotics · doi:10.3390/antibiotics9100661 · Cited by 18
Relating Advanced Electrospun Fiber Architectures to the Temporal Release of Active Agents to Meet the Needs of Next-Generation Intravaginal Delivery Applications
Tyo, K. M., Minooei, F., Curry, K. C., NeCamp, S. M., Graves, D., Fried, J., & Steinbach-Rankins, J. M. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040160 · Cited by 18
Inflammation weakens HIV prevention
Hope, T. J. (2018) · Nature Medicine · doi:10.1038/nm.4534 · Cited by 17
Lessons from a decade of voluntary medical male circumcision implementation and their application to HIV pre-exposure prophylaxis scale up
Reed, J. B., Patel, R. R., & Baggaley, R. C. (2018) · International Journal of STD & AIDS · doi:10.1177/0956462418787896 · Cited by 18
Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men: a discrete choice experiment
Tan, D. H. S., Rana, J., Tengra, Z., Hart, T. A., Wilton, J., & Bayoumi, A. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-01634-3 · Cited by 17
Preference for novel biomedical HIV pre-exposure prophylaxis methods among adolescent girls and young women in Kampala, Uganda: a mixed methods study
Mayanja, Y., Kayesu, I., Kamacooko, O., Lunkuse, J. F., Muturi‐Kioi, V., Price, M. A., Kosidou, K., & Ekström, A. M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1369256 · Cited by 20
Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126
Fischer, K., Nguyen, K., & LiWang, P. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01084-19 · Cited by 17
Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls
Zuend, C. F., Noël‐Romas, L., Hoger, S., McCorriser, S., Westmacott, G., Marrazzo, J. M., Hillier, S. L., Dezzutti, C. S., Squires, K., Bunge, K. E., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002751 · Cited by 16
Polymer Delivery Systems for Long-Acting Antiretroviral Drugs
Nayan, M. U., Panja, S., Sultana, A., Zaman, L. A., Vora, L. K., Sillman, B., Gendelman, H. E., & Edagwa, B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020183 · Cited by 17
Perinatal outcomes associated with pre-exposure prophylaxis for HIV prevention during pregnancy: a systematic review and meta-analysis
Erlwanger, A. S., Rocroi, I., Kirtley, S., & Hemelaar, J. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102532 · Cited by 16
Dapivirine Bioadhesive Vaginal Tablets Based on Natural Polymers for the Prevention of Sexual Transmission of HIV
Cazorla-Luna, R., Martín-Illana, A., Notario-Pérez, F., Bedoya, L. M., Bermejo, P., Ruíz, R., & Veiga, M.-D. (2019) · Polymers · doi:10.3390/polym11030483 · Cited by 16
Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial
Roberts, S. T., Hawley, I., Luecke, E. H., Mensch, B., Wagner, T. M., Hoesley, C. J., McClure, T., Islas, C. P. D., Piper, J. M., Liu, A., et al. (2021) · Journal of Women s Health · doi:10.1089/jwh.2021.0121 · Cited by 16
Emergence of Nanotechnology to Fight HIV Sexual Transmission: The Trip of G2-S16 Polyanionic Carbosilane Dendrimer to Possible Pre-Clinical Trials
Relaño-Rodríguez, I., & Muñoz‐Fernández, M. Á. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249403 · Cited by 15
Nanotechnology-Based Platforms for Vaginal Delivery of Peptide Microbicides
Sánchez‐López, E., Gomara, M. J., & Haro, I. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867328666201209095753 · Cited by 15
An optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae
Shaughnessy, J., Chabeda, A., Tran, T. H. Y., Zheng, B., Nowak, N., Steffens, C., DeOliveira, R. B., Gulati, S., Lewis, L. A., Maclean, J. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975676 · Cited by 15
Next-generation 3D printed multipurpose prevention intravaginal ring for prevention of HIV, HSV-2, and unintended pregnancy
Dahl, D. K., Srinivasan, P., Janusziewicz, R., King, J. L., Shrivastava, R., Zhang, J., Little, D. M., Bachman, S., Kelley, K., Cottrell, M. L., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.059 · Cited by 15
Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial
Husnik, M. J., Brown, E. R., Marzinke, M. A., Livant, E., Palanee‐Phillips, T., Hendrix, C. W., Kiweewa, F. M., Nair, G., Soto-Torres, L. E., Schwartz, K. D., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001503 · Cited by 15
Intravaginal rings for continuous low-dose administration of cervical ripening agents
Wang, Y., Boyd, P., Hunter, A. J., & Malcolm, K. R. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.053 · Cited by 15
Design strategies for long-acting anti-HIV pharmaceuticals
Sang, Y.-L., Ding, L., Zhuang, C., & Chen, F. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.005 · Cited by 15
Topical microbicides for preventing sexually transmitted infections
Obiero, J. A., Ogongo, P., Mwethera, P. G., & Wiysonge, C. S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007961.pub3 · Cited by 16
Antimicrobial Peptide, LL-37, And Its Potential As An Anti-HIV Agent
Vera-Cruz, A., Tanphaichitr, N., & Angel, J. B. (2021) · Clinical and investigative medicine · doi:10.25011/cim.v44i3.36657 · Cited by 15
Drug stability and product performance characteristics of a dapivirine-releasing vaginal ring under simulated real-world conditions
Murphy, D. J., McCoy, C. F., Boyd, P., Derrick, T., Spence, P., Devlin, B., & Malcolm, K. R. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.027 · Cited by 15
Self-citation
Post-use ring weight and residual drug content as potential objective measures of user adherence to a contraceptive progesterone vaginal ring
Murphy, D. J., McCoy, C. F., Plagianos, M. G., RamaRao, S., Merkatz, R. B., Clark, H., Boyd, P., Variano, B., & Malcolm, K. R. (2019) · Contraception · doi:10.1016/j.contraception.2019.06.013 · Cited by 14
Interrogating the promise of long-acting HIV pre-exposure prophylaxis
Pike, C., & Bekker, L. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.11.003 · Cited by 14
Self-citation
The End Is in Sight: Current Strategies for the Elimination of HIV Vertical Transmission
Yang, L. Z., Cambou, M. C., & Nielsen‐Saines, K. (2023) · Current HIV/AIDS Reports · doi:10.1007/s11904-023-00655-z · Cited by 13
Oral preexposure prophylaxis uptake, adherence, and persistence during periconception periods among women in South Africa
Matthews, L. T., Jaggernath, M., Kriel, Y., Smith, P. M., Haberer, J. E., Baeten, J. M., Hendrix, C. W., Ware, N. C., Moodley, P., Pillay, M., et al. (2024) · AIDS · doi:10.1097/qad.0000000000003925 · Cited by 14
Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV ‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists
Sherman, E. M., Agwu, A. L., Ambrosioni, J., Behrens, G. M. N., Chu, C., Collins, L. F., Jimenez, H. R., Koren, D. E., McGorman, L., Nguyen, N. N., et al. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2922 · Cited by 16
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother–infant pairs (MTN-043): a phase 3B, open-label, randomised trial
Noguchi, L., Owor, M., Mgodi, N. M., Mirembe, B. G., Dadabhai, S. S., Horne, E., Gundacker, H. M., Richardson, B. A., Bunge, K. E., Scheckter, R., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(24)00306-0 · Cited by 14
In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection
Giacobbi, N. S., & Sluis‐Cremer, N. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00277-17 · Cited by 14

Authors: Nel, A., van Niekerk, N., Kapiga, S., Bekker, L.-G., Gama, C., Gill, K., Kamali, A., Kotze, P., Louw, C., Mabude, Z., Miti, N., Kusemererwa, S., Tempelman, H., Carstens, H., Devlin, B., Isaacs, M., Malherbe, M., Mans, W., Nuttall, J., Russell, M., Ntshele, S., Smit, M., Solai, L., Spence, P., Steytler, J., Windle, K., Borremans, M., Resseler, S., Van Roey, J., Parys, W., Vangeneugden, T., Van Baelen, B., & Rosenberg, Z.
Affiliations: International Partnership for Microbicides (US)
ORCID: Kapiga, Saidi
Bekker, Linda-Gail
Gill, Katherine
Kotze, Philip
Kusemererwa, Sylvia
Isaacs, Michelle
Nuttall, Jeremy
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-12
Volume: 375
Issue: 22
Pages: 2133-2143
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1602046
OpenAlex: W2558446330
Cited by: 479
References: 16
Citations by year: 2026: 31 · 2025: 39 · 2024: 34 · 2023: 43 · 2022: 50 · 2021: 72 · 2020: 40 · 2019: 78 · 2018: 57 · 2017: 32 · 2016: 3
FWCI: 52.34
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
UpSpace Institutional Repository (University of Pretoria) (submittedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords: dapivirine, vaginal ring, HIV prevention, HIV-1 seroconversion, women, drug safety
MeSH terms: Adolescent, Adult, Double-Blind Method, Female, HIV Seropositivity, Humans, Middle Aged, Pregnancy, Pyrimidines, RNA, Viral, South Africa, Uganda, Vagina, HIV-1, HIV Infections, Incidence, Reverse Transcriptase Inhibitors, Drug Resistance, Viral, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks